Adherence to Teriparatide Treatment and Risk of Fracture: A Systematic Review and Meta-Analysis

Abstract

To conduct a retrospective systematic review and meta-analysis of studies investigating the fracture risk among adherence versus non-adherence patients to treatment for osteoporosis. Cohort studies involving adherence to specifically Teriparatide treatment and the risk of fracture, published from inception to June 10 2019, were identified through PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus database of Systematic Reviews. Five eligible cohort studies were included for analysis. Overall, adherence, compared with nonadherence, had a significant 28% reduction in the risk of all fractures, an 49% reduction in the risk of hip fracture and an 26% reduction in the risk of non-vertebral fracture. Subgroup analyses showed that treatment compliant North American patients had a lower incidence of fracture than treatment compliant Asian patients. The effect size associated with adherence showed no difference with non-adherence when the analysis was limited to a small sample size (<10 000 patients). The findings of this retrospective review indicate that high compliance of Teriparatide treatment result in a decreased risk of fracture, particularly in North American treatment adherence, compared with Asian treatment adherence. Improvement of treatment adherence in patients with osteoporosis should be considered through various means in clinical practice.

Key words

teriparatide - adherence - osteoporosis - fractures - meta-analysis

• References

• 1 Bonjour JP, Ammann P, Rizzoli R. Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int 1999; 9: 379-393
• 2 Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet (London, England) 2002; 359: 1761-1767
• 3 Ioannidis G, Papaioannou A, Hopman WM. et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009; 181: 265-271
• 4 Burge R, Dawson-Hughes B, Solomon DH. et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Mineral Res 2007; 22: 465-475
• 5 Tarride JE, Hopkins RB, Leslie WD. et al. The burden of illness of osteoporosis in Canada. Osteoporos Int 2012; 23: 2591-2600
• 6 Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 2017; 5: 898-907
• 7 Black DM, Abrahamsen B, Bouxsein ML. et al. Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev 2019; 40: 333-368
• 8 Gomberg SJ, Wustrack RL, Napoli N. et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011; 96: 1627-1632
• 9 Hodsman AB, Bauer DC, Dempster DW. et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703
• 10 Diez-Perez A, Marin F, Eriksen EF. et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone 2019; 120: 1-8
• 11 Belhassen M, Confavreux CB, Cortet B. et al. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up. Osteoporos Int 2017; 28: 853-862
• 12 Reyes C, Tebe C, Martinez-Laguna D. et al. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 2017; 28: 2997-3004
• 13 Cheng LI, Durden E, Limone B. et al. Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Special Pharm 2015; 21: 824-833 833a
• 14 Ziller V, Kostev K, Kyvernitakis I. et al. Persistence and compliance of medications used in the treatment of osteoporosis–analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Therap 2012; 50: 315-322
• 15 Merino EM, Álvarez-Gutierrez A, Álvarez CH. et al. Persistence to anti-osteoporosis treatments in primary care patients recorded in the Spanish electronic database BIFAP. NDORMS 2016; 25: 187-188
• 16 Carbonell-Abella C, Pagèscastellà A, Nogués X. et al. Persistence with different antiosteoporosis medications: A population-based cohort study. Osteoporos Int 2013; 24: S187-S188
• 17 Siris ES, Selby PL, Saag KG. et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122: S3-S13
• 18 Ross S, Samuels E, Gairy K. et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 2011; 14: 571-581
• 19 Imaz I, Zegarra P, Gonzalez-Enriquez J. et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21: 1943-1951
• 20 Hutton B, Salanti G, Caldwell DM. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777-784
• 21 Wells G, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013
• 22 Zhao Y, Johnston SS, Smith DM. et al. Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States. Bone 2014; 60: 221-226
• 23 Chan DC, Chang CH, Lim LC. et al. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporos Int 2016; 27: 2855-2865
• 24 Burge RT, Disch DP, Gelwicks S. et al. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int 2017; 28: 799-809
• 25 Burge R, Sato M, Sugihara T. Real-world clinical and economic outcomes for daily teriparatide patients in Japan. J Bone Mineral Metab 2016; 34: 692-702
• 26 Bonafede MM, Shi N, Bower AG. et al. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporos Int 2015; 26: 1203-1212
• 27 Rajzbaum G, Jakob F, Karras D. et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008; 24: 377-384
• 28 Silverman S, Miller P, Sebba A. et al. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int 2013; 24: 2309-2317
• 29 Napoli N, Langdahl BL, Ljunggren O. et al. Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo(R) Observational Study (ExFOS). Calcif Tissue Int 2018; 103: 359-371
• 30 Aloumanis K, Karras D, Drossinos V. et al. Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study. J Osteoporos 2011; 2011: 510398
• 31 Fahrleitner-Pammer A, Langdahl BL, Marin F. et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 2011; 22: 2709-2719
• 32 Langdahl BL, Ljunggren O, Benhamou CL. et al. Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-Month results from the Extended Forsteo Observational Study (ExFOS). Calcif Tissue Int 2016; 99: 259-271
• 33 Soen S, Fujiwara S, Takayanagi R. et al. Japan Fracture Observational Study (JFOS): Patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis. Curr Med Res Opin 2015; 31: 1771-1779
• 34 Miller PD, Silverman SL, Gold DT. et al. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 2006; 17: 85-90
• 35 Soen S, Fujiwara S, Takayanagi R. et al. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Curr Med Res Opin 2017; 33: 2049-2056
• 36 Langdahl BL, Silverman S, Fujiwara S. et al. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 2018; 116: 58-66
• 37 Langdahl BL, Rajzbaum G, Jakob F. et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009; 85: 484-493
• 38 Silverman S, Langdahl BL, Fujiwara S. et al. Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: Integrated analysis of four prospective observational studies. Calcif Tissue Int 2019; 104: 193-200
• 39 Ljunggren O, Benhamou CL, Dekker J. et al. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS). Curr Med Res Opin 2014; 30: 1607-1616
• 40 Rajzbaum G, Grados F, Evans D. et al. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study. Joint Bone Spine Rev Rhumat 2014; 81: 69-75
• 41 Cauley JA. Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthopaed Relat Res 2011; 469: 1891-1899
• 42 Khandelwal S, Chandra M, Lo JC. Clinical characteristics, bone mineral density and non-vertebral osteoporotic fracture outcomes among post-menopausal U.S. South Asian Women. Bone 2012; 51: 1025-1028